Metreleptin for treating lipodystrophy
KEYWORDS: metreleptin, lipodystrophy, treatment, people, company, committee, clinical, liver, experts, partial, section, evidence, noted, partial lipodystrophy, baseline

was 1 remaining area of uncertainty associated with the analyses presented (see the technical report in the final evaluation determination decision making. It discussed issue 1, issues 2 and 3 together; issue 4, issue 6, issue 7, issue 8, issue 9, and issue 10, which were outstanding after technical engagement. When forming the recommendations, the committee took into account the full range of factors that might affect its decision, in particular, the nature of the condition, the clinical effectiveness, value for money and the impact beyond direct health benefits. Nature of the condition Burden of disease 4.5 The patient experts explained the all-consuming nature of lipodystrophy. They highlighted that, other than the serious metabolic abnormalities caused by the condition, hyperphagia was a predominant debilitating feature. The company stated that this feeling of constant hunger was better described as starvation to convey the extent of its debilitating effects. The patient experts explained that eating does not relieve the hunger, so people with the condition are constantly looking for food, which results in physical, psychological and behavioural complications. For children, constant supervision is needed to ensure they do not eat inedible objects. The constant food seeking, and associated lack of concentration and
